Thomas J. Errico, a Director at electroCore, Inc. (NASDAQ:ECOR), has recently enhanced his personal investment in the firm through several documented stock acquisitions. These purchases indicate increased confidence from a key internal stakeholder.
Specifically, on May 21, 2026, Mr. Errico purchased an additional 9,992 shares of electroCore common stock. The cost basis for these shares was $5.99 per share, resulting in a total investment value of $59,852. This timing is notable given the recent performance of the stock; according to InvestingPro data, ECOR had delivered a 13% return over the preceding week and traded at $6.67, which the platform suggests remains undervalued relative to its calculated Fair Value.
Earlier, on May 20, 2026, Mr. Errico completed another acquisition, purchasing 8 shares of common stock at a price of $5.98 per share, totaling $47 for that transaction.
Following these transactions, the total ownership stake held by Mr. Errico in electroCore stands at 360,071 shares. This aggregate holding is detailed as comprising several components: 259,106 shares are owned directly by Mr. Errico; an additional 1,296 shares are managed by a trust established for his family's benefit; and 11,000 shares belong to another trust designated for his personal advantage.
The overall ownership structure also includes 8,872 unvested shares that underlie deferred stock units (DSUs), alongside 69,797 shares that have already vested from previously issued DSUs. All of these transactions were formally reported via a Form 4 filing with the Securities and Exchange Commission on May 26, 2026.
Beyond the insider trading activity, electroCore, Inc. also released significant operational updates. For the first quarter of 2026, the company achieved its highest-ever quarterly revenue, reporting net sales that reached $9.6 million. This figure represents a substantial increase of 43% when compared to the net sales recorded during the same period in the prior year.
However, the financial report also indicated a GAAP net loss of $5.3 million for the quarter. This amount marks an increase from the $3.9 million net loss reported in the first quarter of 2025. Despite the overall net loss figure, the company highlighted other major developments.
In addition to its financial disclosures, electroCore announced that clinical study results had been published in JAMA Network Open. This specific study focused on evaluating the utility of a modified Quell device for treating fibromyalgia. The findings demonstrated the device's effectiveness in mitigating pain when it was utilized in conjunction with standard outpatient physical therapy protocols. The trial itself involved 384 participants, who were divided into two groups that were nearly equal in size: one group used the Quell device while the other did not.
These combined developments underscore electroCore's dual focus on advancing its financial performance metrics and driving progress through critical medical research initiatives. The combination of top-line revenue growth and positive clinical data suggests continued efforts across both commercial operations and scientific advancement for the organization.